Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder

ConferencePositive

AI Analysis

Summary

Eli Lilly presented early-stage data at Psych Congress 2026 demonstrating potential of its GLP-1/GIP receptor agonist candidate for treating depression and alcohol use disorder, expanding the therapeutic applications of its GLP-1 portfolio beyond obesity.

Clinical Trial Data

Phase

early-stage

Outcome Details

Early-stage data presented at Psych Congress 2026 supporting GLP-1/GIP receptor agonist candidate for depression and alcohol use disorder

Importance:5/10

Sentiment:

0.60

GLP-1GIPdepressionalcohol use disorderobesityconference presentation

Related Companies

$LLY

Read the original article

Published by BioSpace on September 22, 2026 3:03 PM

Read Original